COMPANY

AmideBio, LLC

amidebio.com ↗ · Mountain

Keywords: metabolic disease of metabolism

Profile checked Oct 10, 2026

9NIH grants

Timeline

Jul 24, 2025 Grant Government grant — SBIR: $999,468 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Funding

Last 2 years.

Jul 24, 2025 Government grant — SBIR: $999,468 (annual award, as published), announced Jul 24, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

NIH awards 9

Annual award amounts. Total $5.8M.

Aug 26, 2024 NIH award 1R44DK141357-01 FY2024: $929,940 awarded for that fiscal year; activity R44 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Dual Agonist Insulins for Treating Diabetics wi source ↗
Aug 17, 2023 NIH award 5R44DK111304-06 FY2023: $1,405,696 awarded for that fiscal year; activity R44 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Long-acting Stable Glucagons for Treatment of source ↗
Sep 12, 2022 NIH award 2R44DK111304-05 FY2022: $1,287,693 awarded for that fiscal year; activity R44 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Long-acting Stable Glucagons for Treatment of source ↗
Feb 17, 2022 NIH award 5R43DK126521-02 FY2022: $116,045 awarded for that fiscal year; activity R43 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Novel Glucose Responsive Insulin for Improved T source ↗
Feb 26, 2021 NIH award 1R43DK126521-01A1 FY2021: $183,955 awarded for that fiscal year; activity R43 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Novel Glucose Responsive Insulin for Improved source ↗
Aug 12, 2020 NIH award 5R44DK111304-04 FY2020: $816,607 awarded for that fiscal year; activity R44 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Stable Glucagon for Treatment of Hyperinsulinis source ↗
Sep 13, 2019 NIH award 2R44DK111304-03 FY2019: $740,140 awarded for that fiscal year; activity R44 (SBIR); PI FLUDZINSKI, PAWEL; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Stable Glucagon for Treatment of Hyperinsulinis source ↗
Aug 30, 2018 NIH award 5R43DK111304-02 FY2018: $207,286 awarded for that fiscal year; activity R43 (SBIR); PI EISENBERG, STEVE; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Stable Glucagon for Treatment of Hyperinsulinism source ↗
Sep 18, 2017 NIH award 1R43DK111304-01A1 FY2017: $131,102 awarded for that fiscal year; activity R43 (SBIR); PI EISENBERG, STEVE; recipient as written: AMIDEBIO, LLC, LOUISVILLE, CO. Stable Glucagon for Treatment of Hyperinsulini source ↗